October 17, 2017 Article in European Biotechnology, Autumn 2017
Stefan Schmidt (Rentschler Biopharma), M. Scholz (Leukocare)
In the past, the role of customized and tailored formulations have been largely underestimated in the field of biopharmaceutical product development. An advanced formulation strategy can strongly improve the product, leading to significant customer benefits. The growing and increasingly competitive biopharmaceutical market requires individual solutions, particularly for better product stability and prolonged shelf life.
The authors describe in this article the technological base of the Strategic Alliance of Rentschler Biopharma and Leucokare for advanced formulation development agreed earlier this year. Through the integration of Leukocare's unique SPS® formulation platform and Rentschler Biopharma's proven development and manufacturing process, clients gain exciting new opportunities to realize the full potential of their biopharmaceuticals in the market.
Please download our article.
Rentschler Biopharma SE
Dr. Marion Schrader
Senior Director Company Communication and PR